symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TALS,2.82,2.1789,149965,120725892,1.51,0.89-3.29,-0.18,"Talaris Therapeutics, Inc.",USD,0001827506,US87410C1045,87410C104,NASDAQ Global Market,NASDAQ,Biotechnology,https://talaristx.com,"Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.",Ms. Mary Kay Fenton,Healthcare,US,84,502 398 9250,570 South Preston Street,Louisville,KY,40202,,0,https://financialmodelingprep.com/image-stock/TALS.png,2021-05-07,False,False,True,False,False
